NCT01729845View on ClinicalTrials.gov

Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 20, 2012

Primary Completion Date

August 25, 2016

Study Completion Date

April 3, 2017

Conditions
Previously Treated Myelodysplastic SyndromeRecurrent Adult Acute Myeloid Leukemia
Interventions
DRUG

Cytarabine

Given IV

DRUG

Decitabine

Given IV

DRUG

Etoposide

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Mitoxantrone Hydrochloride

Given IV

Trial Locations (3)

98033

EvergreenHealth Medical Center, Kirkland

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

99336

Kadlec Clinic Hematology and Oncology, Kennewick

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT01729845 - Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter